NASDAQ · Biotechnology

BDTX (BDTX) Stock

$1.76 +1.45% NASDAQ: BDTX Healthcare

Valuation

MetricValue
Price$1.76
Market Cap$100.56M
P/E Ratio-1.48
P/B Ratio0.95
P/S Ratio1.41
EPS (TTM)$0.39
52-Week High$4.94
52-Week Low$1.61
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-35.16%
ROA-18.57%
ROCE17.86%
Gross Margin28.57%
Operating Margin28.57%
Net Margin31.43%
Debt/Equity0.17
Current Ratio8.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$70.0M
Operating Profit$-127.0M$-93.0M$-86.0M$-79.0M$20.0M
Net Profit$-126.0M$-91.0M$-82.0M$-70.0M$22.0M
EPS$-3.47$-2.52$-1.88$-1.27$0.39
Op Margin————28.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$248.0M$156.0M$159.0M$123.0M$143.0M
Total Liabilities$52.0M$41.0M$42.0M$39.0M$31.0M
Cash$66.0M$34.0M$56.0M$36.0M$21.0M
Borrowings$28.0M$28.0M$25.0M$22.0M$19.0M

Latest News

Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path MarketBeat · Jun 6, 2026 BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst Zacks · May 27, 2026 Black Diamond Stock Outlook After Q1 Beat and Cash Runway Zacks · May 27, 2026 BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know Zacks · May 27, 2026 BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data Zacks · May 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-100.0M$-85.0M$-67.0M$-62.0M$30.0M
Investing Cash Flow$128.0M$53.0M$16.0M$17.0M$-45.0M
Financing Cash Flow$0$0$0$1.0M$0
Net Cash Flow$31.0M$-32.0M$22.0M$-20.0M$-15.0M
Free Cash Flow$-103.0M$-85.0M$-67.0M$-62.0M$30.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-1.12
EV / EBITDA4.83
FCF Yield-34.53%
Quick Ratio8.46
Interest Coverage—
Return 1Y-37.46%
Return 3Y-61.96%
Return 5Y-81.62%

Ownership

Insiders Held0.65%
Institutions Held67.24%
Institutions Float Held67.68%
Institutional HolderSharesReport Date
T. Rowe Price Investment Management, Inc.10,563,1032026-03-31
NEA Management Company, LLC4,448,7572026-03-31
Acadian Asset Management. LLC2,348,6512026-03-31
Vanguard Capital Management LLC1,850,4682026-03-31
Renaissance Technologies, LLC1,643,7472026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AARD $6.42 -4.04% -1.62 $140.50M 0.00%
ABEO $7.14 +3.48% 5.14 $406.94M 0.00%
AVTX $18.97 +2.87% -2.79 $214.25M 0.00%
CRBU $1.65 +0.61% -1.25 $163.65M 0.00%
ENTA $12.61 -0.94% -6.04 $366.68M 0.00%

About BDTX

BDTX is led by CEO Mark A. Velleca, employs 24 people, headquartered in US, publicly traded since 2020.

BDTX stock trades at $1.76 with a market capitalization of $100.56M. The stock is valued at a price-to-earnings (P/E) ratio of -1.48, price-to-book of 0.95, price-to-sales of 1.41. Over the past 52 weeks the stock has ranged between $1.61 and $4.94, and currently trades 64.4% below its 52-week high.

On profitability, BDTX generates a return on equity (ROE) of -35.16%, return on capital employed of 17.86%, an operating margin of 28.57%, a net profit margin of 31.43%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides